Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2010

View Archived Issues

Pfizer reports on discovery and evaluation of PF-610355 for asthma/COPD

Alipogene tiparvovec shows safety and efficacy in subjects with LPL deficiency / News in Context

B7-H4 gene therapy combined with abatacept enhances experimental islet graft survival

PF-4457845 development and early clinical data reported at recent congresses

New GHRH receptor antagonists disclosed by sanofi-aventis

Faxeladol shows comparable safety and efficacy to tramadol in patients with painful polyneuropathy

E.U. approves Brinavess for rapid conversion of recent-onset AF

FDA updates Tygacil label to include increased mortality risk

FDA approves Omnitrope for idiopathic short stature

Biousian Biotechnology describes new delta-type opioid receptor agonists

PecFent receives European marketing authorization for breakthrough cancer pain

Halozyme begins phase II trials of PH-20 in type 1 and type 2 diabetes

New alpha 2B and 2C adrenoceptor agonists claimed by Allergan

NIH grants funding to Bionovo for obesity and metabolic syndrome study

LG Life Sciences discloses new xanthine oxidase inhibitors

MorphoSys and Absynth partner for MRSA treatments

Organon and Pharmacopeia claim new TRPV1 ligands

Eisai initiates phase I study of BAN-2401 in AD

Orexigen and Takeda to co-commercialize Contrave in North America

E.C. approves Seroquel XR as add-on treatment for major depressive disorder

Results reported from study of Cerus' INTERCEPT Blood System

iBio, Fraunhofer and GE Healthcare to partner for iBioLaunch platform

NIH awards Celsion grant to develop new oncology treatments

Ipsen gains rights to fipamezole outside of North America and Japan

MSD's Sycrest approved in Europe for biopolar disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...